StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Get Free Report) in a report issued on Sunday. The firm set a “sell” rating on the stock. Several other analysts have also recently ...

OncoCyte (OCX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Bio-Rad Laboratories, Inc.’s BIO Clinical Diagnostics business is back to its usual growth trajectory post-pandemic while maintaining a strong market position worldwide for key platforms. The ...